A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.
about
Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women.Toward a Cancer Drug of Fungal OriginNatural product and natural product derived drugs in clinical trials.A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
P2860
A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
A phase I pharmacokinetic and ...... with refractory solid cancer.
@en
A phase I pharmacokinetic and ...... with refractory solid cancer.
@nl
type
label
A phase I pharmacokinetic and ...... with refractory solid cancer.
@en
A phase I pharmacokinetic and ...... with refractory solid cancer.
@nl
prefLabel
A phase I pharmacokinetic and ...... with refractory solid cancer.
@en
A phase I pharmacokinetic and ...... with refractory solid cancer.
@nl
P2093
P50
P1476
A phase I pharmacokinetic and ...... s with refractory solid cancer
@en
P2093
Dal-Hyun Kim
Hei-Cheul Jeung
Jae Kyung Roh
Kyung Soo Park
P2860
P2888
P304
P356
10.1007/S10637-009-9287-8
P577
2009-07-08T00:00:00Z